Finvest
UTHR Biotechnology · Rare disease · Profitable biotech · Pulmonary hypertension · Thesis updated July 12, 2026

Clinical wins meet a real Tyvaso rival

01 Running thesis

Pipeline proof, harder sales test

The bull case is stronger on science than it was a year ago. Ralinepag met its main Phase 3 goal in PAH, with a 55% cut in the risk of clinical worsening. Tyvaso also posted positive TETON-1 results in idiopathic pulmonary fibrosis, a lung-scarring disease often called IPF. Together, those wins give United Therapeutics a clearer path toward management's $4 billion annual revenue run-rate goal by 2027.

The company is not starting from a weak base. Tyvaso DPI, the dry powder inhaler version of treprostinil, grew 9% to $330.3 million in Q1 2026. Orenitram reached $135.6 million, up 12% year over year. Management also authorized a $2 billion share repurchase program, which signals confidence and can support per-share value.

The bear case has changed. It is less about whether the next drugs work in trials, and more about whether the company can launch them well while defending Tyvaso. Q1 2026 revenue fell 2% to $781.5 million, mainly because Nebulized Tyvaso dropped 22%. Liquidia's Yutrepia, launched in June 2025, is now a named rival to Tyvaso DPI, Nebulized Tyvaso, and other treprostinil products.

That makes the stock a quality biotech with a live execution test. Finn's scores fit that split: strong financial health and business performance, but only middling growth, valuation, and sentiment. The company has real assets, yet the market still has to decide how much of the 2027 growth target is already in the price.

May 2026→Q1 2026 showed a 2% revenue decline and a sharper drop in Nebulized Tyvaso, while Tyvaso DPI and Orenitram kept growing. The same update added a clearer growth path from positive ralinepag and TETON-1 data, but also confirmed Yutrepia as an active direct competitor.
Feb 2026▲Full-year 2025 revenue reached $3.18 billion, and management reaffirmed its $4 billion annual revenue run-rate target by 2027. Tyvaso DPI growth and a clearer launch plan supported the bull case.
Apr 2025▲The starting thesis was a profitable rare disease company with 18 straight quarters of revenue growth and a strong Tyvaso franchise. The key long-term option was xenotransplantation, while the main watch item was the path to the 2027 revenue goal.
02 Business model

Treprostinil pays the bills

United Therapeutics makes most of its money by selling rare disease drugs, mainly treprostinil-based treatments for pulmonary hypertension. Pulmonary hypertension means high blood pressure in the blood vessels of the lungs. These diseases are serious, chronic, and treated by specialists, which can support high drug prices when the medicine works.

The moat comes from drug delivery and doctor trust. Tyvaso DPI is easier for many patients than a nebulized form, so the company has been moving patients toward the dry powder inhaler. That helps protect the franchise even as older forms, such as Remodulin and Nebulized Tyvaso, face pressure.

The weak point is concentration. If Tyvaso loses share faster than Tyvaso DPI, Orenitram, ralinepag, and new uses for Tyvaso can grow, the revenue story gets harder. The business model works best when United Therapeutics keeps patients, wins new labels, and keeps payers from pushing patients toward rivals.

03 Product portfolio

What United sells and what comes next

Growth engine

Tyvaso DPI

This is the dry powder inhaler version of treprostinil and the company's largest named product line in Q1 2026. Sales were $330.3 million, up 9% year over year.

Cash cow

Nebulized Tyvaso

This older inhaled form still matters, but it is shrinking as the mix shifts. Q1 2026 sales were $127.2 million, down 22% year over year.

Steady

Orenitram

Orenitram is an oral treprostinil treatment. It reached record quarterly revenue of $135.6 million in Q1 2026, up 12% year over year.

Cash cow

Remodulin

Remodulin is an infused treprostinil product. It still brings in meaningful sales, but faces generic competition and declined 8% year over year in Q1 2026.

Option

Ralinepag

Ralinepag is a next wave PAH drug. Its Phase 3 ADVANCE OUTCOMES trial met the main goal, and the company plans to submit an NDA in summer 2026.

Option

Tyvaso for IPF

Tyvaso may expand into idiopathic pulmonary fibrosis after positive TETON-1 results. Approval would open a new market beyond the current Tyvaso base.

Option

UHeart xenotransplantation

UHeart is a long-range program that aims to use animal organs for human transplant. It has FDA clearance to start a first-in-human xenoheart trial, but the path is long and uncertain.

04 Business segments

Q1 sales mix is still Tyvaso-heavy

Tyvaso DPI42%modest
Nebulized Tyvaso16%declining
Orenitram17%modest
Remodulin16%declining
Other products and revenue8%flat

This mix uses Q1 2026 revenue of $781.5 million from the 10-Q. It treats product lines as the useful investor view, because the company is highly concentrated in treprostinil products.

05 Risk factors

What could break the story

Yutrepia takes Tyvaso share

High impact · Medium odds

Liquidia's Yutrepia launched in June 2025 and the 10-Q says it competes directly with Tyvaso DPI, Nebulized Tyvaso, and other treprostinil products. If doctors or payers push patients toward Yutrepia, United Therapeutics could lose sales and pricing power in its core franchise.

We watchTrack Tyvaso DPI growth, total Tyvaso revenue, and any payer comments about switching patients to Yutrepia.

Launches do not match the trial data

High impact · Medium odds

Ralinepag and Tyvaso for IPF now have positive pivotal data, so the risk has moved to filings, approvals, labels, and sales execution. A clean approval still may not mean a fast launch if doctors move slowly or reimbursement is difficult.

We watchWatch the ralinepag NDA submission in summer 2026, FDA review updates, label wording, and early prescription trends after launch.

Nebulized Tyvaso keeps falling

Medium impact · High odds

Nebulized Tyvaso sales fell 22% year over year in Q1 2026. Some of that is a planned mix shift to Tyvaso DPI, but it still creates a hole that the growing inhaler must fill.

We watchCompare Tyvaso DPI growth against the decline in Nebulized Tyvaso each quarter.

Too much depends on treprostinil

High impact · Medium odds

United Therapeutics is profitable and focused, but most revenue still comes from treprostinil-based products. That focus can be a strength when the franchise grows, and a weakness if competition or safety issues hit the drug family.

We watchTrack the share of revenue from Tyvaso, Orenitram, and Remodulin versus newer non-treprostinil products.

UHeart stays far from revenue

Low impact · High odds

The UHeart xenotransplantation program is bold, but it is still very early. FDA clearance to begin a human trial is not the same as proof of safety, approval, or commercial demand.

We watchFollow first-in-human trial enrollment, safety updates, and FDA feedback before assigning material revenue value.
06 Quick answers

In one breath

What does United Therapeutics do?

United Therapeutics develops and sells rare disease medicines, mainly for pulmonary hypertension. Its biggest business is treprostinil, sold through products such as Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Remodulin.

Why does Tyvaso matter so much?

Tyvaso is the company's largest product family and the main reason investors watch United Therapeutics. Tyvaso DPI grew in Q1 2026, but Nebulized Tyvaso fell, so the mix shift is important.

What is the main new risk for UTHR?

The clearest new risk is Liquidia's Yutrepia. It launched in June 2025 and now competes directly with Tyvaso DPI and Nebulized Tyvaso.

What are the next big catalysts?

The next big items are the ralinepag NDA planned for summer 2026, regulatory progress for Tyvaso in IPF, and the market response to Yutrepia. Investors should also watch the $2 billion buyback and early UHeart trial progress.